Radiofrequency Ablation of Breast Cancer: A Retrospective Study

Ito, Toshikazu; Oura, Shoji; Nagamine, Shinji; Takahashi, Masato; Yamamoto, Nobuto; Yamamichi, Noboru; Earashi, Mitsuharu; Doihara, Hiroyoshi; Imoto, Shigeru; Mitsuyama, Shoshu; Akazawa, Kohei

doi:10.1016/j.clbc.2017.09.007

Cited by 39 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among them, the most reported is RFA. Ito et al reported that 386 patients treated with RFA at 10 centers from 2003 to 2009 had a 5-year intra-breast recurrence-free rate of 97% for sizes ≤ 1.0 cm, 94% for 1.1 to 2.0 cm, and 87% for > 2.0 cm or more, respectively [16]. Nguyen et al [17] reviewed 30 studies, 643 cases of RFA and reported that complete ablation rates ranged from 100 to 44% with a median of 88%.…”

Section: Discussionmentioning

confidence: 99%

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

et al. 2020

View full text Add to dashboard Cite

Background and purpose Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020. Materials and methods Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy [relative biological efficacy (RBE)]. After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbonion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results. Conclusions The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbonion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thermal ablation is already used in clinical practice for primary and metastatic malignant liver, breast, renal, bone and lung tumors [20][21][22][23] but is not yet regularly used for TNs, despite their validation in Korean and Italian studies [24][25][26][27][28]. Radiofrequency ablation (RFA), and laser ablation have already been studied separately for the treatment of benign TNs [29][30][31][32][33][34] and in many retrospective and some prospective comparative studies with a long-term follow-up.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of thermal ablation (radiofrequency and laser): should we treat all types of thyroid nodules?

Hamou¹,

Ghanassia

Espiard³

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Chemotherapy, radiotherapy, and immunotherapy are recommended for the treatment of BC patients with metastatic disease. Although great progresses (including the discovery of novel therapeutic targets and the understanding of mechanisms of resistance to treatment) have been made for the management of patients with metastatic BC, the disease remains incurable, which causes at least half a million deaths related to the disease per year [ 6 – 11 ]. Therefore, it is important to develop novel prognostic markers associated with clinical outcomes of BC patients and to develop targeted agents that disrupt specific biological processes critical to growth of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients

2018

View full text Add to dashboard Cite

BackgroundThe clinical outcome of patients with breast cancer (BC) remains poor.Material/MethodsWe analyzed BC microarray studies GSE37751, GSE7390, and GSE21653 to investigate the expression of FGF5 gene between BC patients and their normal counterparts and the relationship between FGF5 expression and age, tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, clinical risk group according to NPI criteria, clinical risk group according to Veridex signature, distant metastasis-free survival (DMFS), time to distant metastasis (TDM), disease-free survival (DFS), and overall survival (OS) of BC patients. Gene set enrichment analysis (GSEA) was used to investigate the exact mechanisms.ResultsFGF5 expression was significantly upregulated in BC patients relative to that in normal controls (P<0.0001). BC patients in the FGF5 low-expression group were correlated with better clinical characteristics, including tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, NPI criteria and Veridex signature, DMFS, TDM, and DFS compared with those in the FGF5 high-expression cohort. The result of GSEA indicated that FGF5 inhibits the proliferation of BC cells via ultraviolet response and TGF-β signaling. Quantitative PCR verified that FGF5 was overexpressed in patients with BC.ConclusionsOur results suggest that FGF5 is an independent protective factor for BC patients.

show abstract

Radiofrequency Ablation of Breast Cancer: A Retrospective Study

Abstract: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.

Cited by 39 publications

References 31 publications

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

Safety and efficacy of thermal ablation (radiofrequency and laser): should we treat all types of thyroid nodules?

Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients

Contact Info

Product

Resources

About